A phase 2a trial of the IL-33 monoclonal antibody tozorakimab in patients with COPD: FRONTIER-4
Although the primary end-point was not met in the intent-to-treat population, tozorakimab showed positive efficacy signals <i>versus</i> placebo in a subgroup of patients with COPD with a high risk of exacerbations.
Authors
- Maria G. Belvisi (ORCID: https://orcid.org/0000-0003-1652-4370)
- Chris Kell
- Aoife Kelly
- Rachel Moate
- Luis Mateos Caballero
- Muhammad Waqas Sadiq (ORCID: https://orcid.org/0000-0003-3331-0702)
- Fred Reid
- Patricia Guller
- Ioannis Psallidas (ORCID: https://orcid.org/0000-0001-7284-0111)
- Sarah Doffman
- Lars H. Nordenmark (ORCID: https://orcid.org/0000-0002-7139-8816)
- Dave Singh (ORCID: https://orcid.org/0000-0001-8918-7075)
- Hitesh Pandya (ORCID: https://orcid.org/0000-0003-0514-2529)
- Joanna Kiraga
- Rebecca Smith (ORCID: https://orcid.org/0000-0002-3819-7991)
- Ulla Seppälä
- Dennis E. Brooks
- Eulalia Jiménez (ORCID: https://orcid.org/0009-0006-4351-8063)
Institutions
- AstraZeneca (United Kingdom) (GB)
- Manchester University NHS Foundation Trust (GB)
- AstraZeneca (Australia) (AU)
- AstraZeneca (Singapore) (SG)
- AstraZeneca (Brazil) (BR)
- Instituto de Arqueología-Mérida (ES)
- AstraZeneca (Switzerland) (CH)
- AstraZeneca (Poland) (PL)
- AstraZeneca (Finland) (FI)
- AstraZeneca (Sweden) (SE)
- AstraZeneca (Spain) (ES)
- AstraZeneca (United States) (US)
- Medicines Evaluation Unit (GB)
- Imperial College London (GB)
- National Patient Safety Foundation (US)
Publication Details
- Journal
- European Respiratory Journal
- Published
- 2025-03-28
- DOI
- https://doi.org/10.1183/13993003.02231-2024
- Citations
- 36
- Primary Topic
- IL-33, ST2, and ILC Pathways
- Type
- article
- Field-Weighted Citation Impact
- 28.71
Funders
- AstraZeneca